Background: Children in remission from acute lymphoblastic leukemia (ALL) have a high prevalence of immune system defects; one of them is the decrease of vaccine-induced antibody seropositivity rates. This antibody deficiency may place children with ALL at risk for the development of vaccine-preventable diseases, even after completion of chemotherapy, and they could function as a reservoir for additional spread of these diseases in the population. The aim of the present study was the assessment of the levels of vaccine-induced antibodies against measles and rubella viruses in ALL children following chemotherapy. Subjects and methods: Antibody levels against measles and rubella vaccine viruses were evaluated by ELISA technique in 96 children with ALL after completion of chemotherapy, in addition to 30 healthy children (non cancer controls of matched age and sex). Results: All healthy children were seropositive for measles and rubella antibodies.On the other hand, out of 96 children who received chemotherapy, only 19 (19.8%) were seropositive for measles antibodies, while 70 (72.9%) were seropositive for rubella antibodies. Most of measles seropositive cases (57.9%) had low levels of measles antibodies while among control group most children (56.7%) had high levels of measles antibodies. Similarly among children who received chemotherapy, most of the seropositive cases (45.7%) had low levels of rubella antibodies, while among control group, most of children (36.6%) had high levels of rubella antibodies. Seropositivity rate of measles was found to be related to the age at diagnosis and disease duration, while that of rubella was found to be related to the disease duration only. Conclusion and recommendations: Most of children who have been treated with chemotherapy for ALL had lost measles antibodies and to less extent rubella antibodies. Among seropositive cases, levels of measles and rubella antibodies are low following treatment with chemotherapy compared to levels among normal controls. Therefore, revaccination of children with ALL following completion of chemotherapeutic treatment against measles and rubella is recommended.
INTRODUCTION
Measles is a highly contagious, serious viral disease. It remains a leading cause of death among young children globally, despite the availability of a safe and effective vaccine. Children usually do not die only from measles, but from its complications such as pneumonia and diarrhea as a result of the immunosuppression associated with measles infection. (1) On the other hand rubella, is a mild viral disease as long as it is not contracted during pregnancy, otherwise it is the leading cause of miscarriage, stillbirth or the risk of congenital rubella syndrome (CRS) in a large proportion of children born to infected mothers. (2) In the early 1970s, a triple vaccine containing attenuated measles, mumps and rubella viruses (MMR) was introduced worldwide. (3) MMR vaccine played a major role in decreasing the morbidity and mortality rate worldwide, its effectiveness depends mainly on the age at vaccination and receipt of a booster dose. (4) The objective is to provide two doses ofMMR vaccine at appropriate intervals for all eligible individuals.Over 90% of individuals will seroconvert to measles, mumps and rubellaantibodies after the first dose of the MMR vaccines. (5) The first dose of MMR should be given ideally at thirteen monthsof age, as the immunization before this age providesearlier protection in localities where therisk of measles is higher, but residualmaternal antibodies may reduce the response rate to the vaccine. The optimalage chosen for scheduling children is therefore a compromise between risk ofdisease and level of protection. (6) A second dose is normally given before school entry but can be given routinelyat anytime from three months after the first dose. Comprehensive vaccination has dramatically decreased measles morbidity and mortality, both in developing countries and the developed world. In 2010, the World Health Assembly established three milestones for measles eradication to be reached by 2015. (8, 9) Cancer and its treatment are important causes of secondary immunodeficiency in childhood. (10) Leukemia constitutes the most frequent malignancy in the pediatric (14, 15) Children who were treated with chemotherapy had lower levels of antibodies against common viral vaccination antigens such asmeasles ,mumps, rubella, and polio which results in transient immunodeficiency. (16, 17) This antibody deficiency may place children with ALL at risk for the development of vaccine-preventable diseases, even after completion of chemotherapy, and they could function as a reservoir for additional spread of these diseases in the population. (18) In particular, it has yet to be established whether the degree of immune dysfunction after standard chemotherapy demands a booster dose outside the recommended schedule, revaccination, or no intervention at all. (18, 19) The aim of the present study was the assessment of the levels of vaccineinduced antibodies against measles and rubella viruses in ALL children following chemotherapy.
Subjects and methods
This cross sectional study was carried out 
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To indicate statistical significance, the threshold for p values was taken at 5% level (p < 0.05). All tests used in this study were two-sided.
RESULTS

Antibody titers to measles and rubella
were measured in ALL children after cessation of therapy and in their matched controls. (20) Rubella is a mild disease as long as the infected female is not pregnant; otherwise CRS is the major consequence of rubella infection during pregnancy. which may place these children at risk for the development of vaccine-preventable diseases. (22, 23) In this study (25) evaluated a group of 39 children who were treated for leukemia (and who had been vaccinated previously for MMR) at diagnosis and at the end of chemotherapy. They found decreases in seropositivity rates of 13% for measles, 18%
for mumps, and 21% for rubella.
Nilsson et al., (2002) (18) analyzed (18) who demonstrated that the antibody levels against measles and rubella viruses were significantly higher before than after completed chemotherapy in positive cases.
Viana et al., (2012) (27) (12) showed that the age at diagnosis is not a significant factor in the presence of both measles and rubella
antibodies.
In the current study, the role of the 
